NASDAQ:LIVN LivaNova - LIVN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LivaNova PLC Please log in to your account or sign up in order to add this asset to your watchlist. $42.71 +0.41 (+0.97%) (As of 03/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$42.28▼$42.9150-Day Range$40.84▼$58.1452-Week Range$40.26▼$88.00Volume350,438 shsAverage Volume543,881 shsMarket Capitalization$2.29 billionP/E RatioN/ADividend YieldN/APrice Target$76.20 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media LivaNova MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside78.4% Upside$76.20 Price TargetShort InterestHealthy3.62% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth17.83%From $2.58 to $3.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector124th out of 1,009 stocksElectromedical Equipment Industry2nd out of 23 stocks 3.4 Analyst's Opinion Consensus RatingLivaNova has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.20, LivaNova has a forecasted upside of 78.4% from its current price of $42.71.Amount of Analyst CoverageLivaNova has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.62% of the outstanding shares of LivaNova have been sold short.Short Interest Ratio / Days to CoverLivaNova has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LivaNova has recently decreased by 13.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLivaNova does not currently pay a dividend.Dividend GrowthLivaNova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LIVN. Previous Next 2.6 News and Social Media Coverage News SentimentLivaNova has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for LivaNova this week, compared to 2 articles on an average week.Search Interest3 people have searched for LIVN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added LivaNova to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LivaNova insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.38% of the stock of LivaNova is held by insiders.Percentage Held by Institutions98.89% of the stock of LivaNova is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for LivaNova are expected to grow by 17.83% in the coming year, from $2.58 to $3.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LivaNova is -26.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LivaNova is -26.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLivaNova has a P/B Ratio of 1.89. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About LivaNova (NASDAQ:LIVN) StockLivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiopulmonary and Other segments. The Cardiopulmonary segment is involved in the development, production and sale of cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, and related accessories. The Other segment includes heart valves business and corporate shared service expenses for finance, legal, human resources, information technology, and corporate business development. The company was founded in 1987 and is headquartered in London, the United Kingdom.Read More Receive LIVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter. Email Address LIVN Stock News HeadlinesFebruary 28, 2023 | finance.yahoo.comDown -12.75% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)February 23, 2023 | finance.yahoo.comLivaNova Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsMarch 30, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 10, 2023 | finance.yahoo.comLivaNova PLC (LIVN) Stock Historical Prices & Data - Yahoo FinanceJanuary 7, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of LivaNova PLC (NASDAQ:LIVN)December 15, 2022 | finance.yahoo.comShareholders in LivaNova (NASDAQ:LIVN) are in the red if they invested five years agoNovember 24, 2022 | finance.yahoo.comShould You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?November 7, 2022 | finance.yahoo.comLivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On CapitalMarch 30, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …November 2, 2022 | finance.yahoo.comLivaNova Reports Third-Quarter 2022 ResultsOctober 26, 2022 | finance.yahoo.comLivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?October 21, 2022 | finance.yahoo.comBreakeven Is Near for LivaNova PLC (NASDAQ:LIVN)October 19, 2022 | globenewswire.comVentricular Assist Devices Market Report (2022 to 2030) - Abiomed, Inc., Medtronic Plc, Abbott Laboratories, LivaNova PLC, Boston Scientific Corporation and Jarvik Heart, Inc - GlobeNewswireOctober 13, 2022 | seekingalpha.comLivaNova Loses Profit Momentum On Higher R&D Expense (NASDAQ:LIVN) - Seeking AlphaOctober 6, 2022 | finance.yahoo.comGlobal Heart Lung Machine Market Report to 2031 - Industry Analysis, Size, Share, Growth, Trends, and Forecasts - Yahoo FinanceOctober 6, 2022 | globenewswire.comWith 5.3% CAGR, Defibrillator Market Size worth USD - GlobeNewswireOctober 5, 2022 | globenewswire.comAt 5.6% CAGR, Global Medical Perfusion Technology Market Size to Hit USD 905.50 Million by 2026: Facts & Factors - GlobeNewswireSeptember 30, 2022 | nasdaq.com21%of this LivaNova PLC (NASDAQ:LIVN) insider's holdings were sold in the last year - NasdaqSeptember 30, 2022 | benzinga.comFDA Says Livanova Recalls Lifesparc System For Risk Of Unintentional Extended Pump Stop During Controller - BenzingaSeptember 30, 2022 | seekingalpha.comFDA labels recall of blood bypass pump systems by LivaNova as most serious - Seeking AlphaSeptember 30, 2022 | nasdaq.comLivaNova Enters Oversold Territory (LIVN)September 27, 2022 | finance.yahoo.comNeuromodulation Devices Global Market - Forecast To 2029 - Yahoo FinanceSeptember 26, 2022 | benzinga.comWorldwide Heart Lung Machine Industry to 2031 - Featuring Hemovent, LivaNova, Medtronic and Nipro Among O - BenzingaSeptember 16, 2022 | finance.yahoo.comOutlook on the Endoscopic Vessel Harvesting System Global Market to 2027 - Growing Healthcare Market Presents Opportunities - Yahoo FinanceSeptember 14, 2022 | bizjournals.com2022 Fire Awards, Exits of the Year: ALung Technologies - The Business JournalsSeptember 12, 2022 | finance.yahoo.comInternal Neurostimulation Devices Market is Thriving at CAGR Of +17.4% by 2029, Size, Share, Emerging Trends, Historic Analysis, Competitive Landscape and Industry Growth Factors - Yahoo FinanceSeptember 8, 2022 | bizjournals.comCarlson Center's small neighbors sign new tenants, including Roers Cos. - The Business JournalsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LIVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter. Email Address LIVN Company Calendar Last Earnings2/22/2023Today3/30/2023Next Earnings (Confirmed)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LIVN CUSIPN/A CIK1639691 Webwww.livanova.com Phone442033250660Fax281-218-9332Employees2,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$76.20 High Stock Price Forecast$95.00 Low Stock Price Forecast$62.00 Forecasted Upside/Downside+79.8%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.62) Trailing P/E RatioN/A Forward P/E Ratio16.43 P/E GrowthN/ANet Income$-86,250,000.00 Net Margins-8.44% Pretax Margin-7.35% Return on Equity10.49% Return on Assets5.58% Debt Debt-to-Equity Ratio0.43 Current Ratio2.98 Quick Ratio2.54 Sales & Book Value Annual Sales$1.02 billion Price / Sales2.22 Cash Flow$6.29 per share Price / Cash Flow6.74 Book Value$22.56 per share Price / Book1.88Miscellaneous Outstanding Shares53,560,000Free Float53,361,000Market Cap$2.27 billion OptionableOptionable Beta0.87 Key ExecutivesDamien McDonaldChief Executive Officer & Executive DirectorAlex ShvartsburgChief Financial OfficerBryan D. OlinSenior Vice President & Head-Product DevelopmentMichael David HutchinsonSecretary, Chief Legal Officer & Senior VPMarco DolciPresident-CardiopulmonaryKey CompetitorsTransMedics GroupNASDAQ:TMDXIntegerNYSE:ITGRInModeNASDAQ:INMDCONMEDNYSE:CNMDOutset MedicalNASDAQ:OMView All CompetitorsInsiders & InstitutionsVictory Capital Management Inc.Bought 147,270 shares on 3/10/2023Ownership: 1.994%Voya Investment Management LLCSold 11,136 shares on 2/28/2023Ownership: 0.070%Teachers Retirement System of The State of KentuckyBought 1,300 shares on 2/22/2023Ownership: 0.016%Macquarie Group Ltd.Bought 582 shares on 2/21/2023Ownership: 0.120%Point72 Middle East FZEBought 1,290 shares on 2/16/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions LIVN Stock - Frequently Asked Questions Should I buy or sell LivaNova stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIVN shares. View LIVN analyst ratings or view top-rated stocks. What is LivaNova's stock price forecast for 2023? 4 brokerages have issued 12-month price targets for LivaNova's stock. Their LIVN share price forecasts range from $62.00 to $95.00. On average, they expect the company's stock price to reach $76.20 in the next twelve months. This suggests a possible upside of 78.4% from the stock's current price. View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts. How have LIVN shares performed in 2023? LivaNova's stock was trading at $55.54 at the beginning of the year. Since then, LIVN stock has decreased by 23.1% and is now trading at $42.71. View the best growth stocks for 2023 here. Are investors shorting LivaNova? LivaNova saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 1,940,000 shares, a decline of 13.0% from the February 28th total of 2,230,000 shares. Based on an average trading volume of 523,900 shares, the short-interest ratio is presently 3.7 days. View LivaNova's Short Interest. When is LivaNova's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our LIVN earnings forecast. How can I listen to LivaNova's earnings call? LivaNova will be holding an earnings conference call on Wednesday, May 3rd at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were LivaNova's earnings last quarter? LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, February, 22nd. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.09. The business earned $274.90 million during the quarter, compared to analyst estimates of $262.16 million. LivaNova had a negative net margin of 8.44% and a positive trailing twelve-month return on equity of 10.49%. The firm's revenue for the quarter was up 1.8% on a year-over-year basis. During the same quarter last year, the company earned $0.57 earnings per share. What ETFs hold LivaNova's stock? ETFs with the largest weight of LivaNova (NASDAQ:LIVN) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), VanEck Morningstar SMID Moat ETF (SMOT), Simplify Health Care ETF (PINK), Invesco Nasdaq Future Gen 200 ETF (QQQS), Vanguard S&P Mid-Cap 400 Value ETF (IVOV), iShares U.S. Medical Devices ETF (IHI), Vanguard Russell 2000 Growth ETF (VTWG) and Principal U.S. Small-Cap Multi-Factor ETF (PSC). What guidance has LivaNova issued on next quarter's earnings? LivaNova updated its FY23 earnings guidance on Wednesday, February, 22nd. The company provided EPS guidance of $2.45-2.65 for the period, compared to the consensus EPS estimate of $2.48. What is Damien McDonald's approval rating as LivaNova's CEO? 47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees. What other stocks do shareholders of LivaNova own? Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP). What is LivaNova's stock symbol? LivaNova trades on the NASDAQ under the ticker symbol "LIVN." Who are LivaNova's major shareholders? LivaNova's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Barrow Hanley Mewhinney & Strauss LLC (4.33%), Harris Associates L P (3.75%), Eminence Capital LP (3.25%), Morgan Stanley (3.08%), Dimensional Fund Advisors LP (2.04%) and Victory Capital Management Inc. (2.00%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci. View institutional ownership trends. How do I buy shares of LivaNova? Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is LivaNova's stock price today? One share of LIVN stock can currently be purchased for approximately $42.71. How much money does LivaNova make? LivaNova (NASDAQ:LIVN) has a market capitalization of $2.29 billion and generates $1.02 billion in revenue each year. The company earns $-86,250,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. How many employees does LivaNova have? The company employs 2,900 workers across the globe. How can I contact LivaNova? LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for the company is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332. This page (NASDAQ:LIVN) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.